300750 Contemporary Amperex Technology (A)

DGAP-News: Armacell Group: Armacell 9M 2019 Results

DGAP-News: Armacell Group / Key word(s): Quarter Results/Miscellaneous
Armacell Group: Armacell 9M 2019 Results

12.11.2019 / 16:00
The issuer is solely responsible for the content of this announcement.


Press release

Armacell 9M 2019 Results

  • Net sales of EUR 486.3 million
  • Adjusted EBITDA of EUR 98.1 million
  • Adjusted EBITDA margin at 20.2%

Luxembourg, 12 November 2019 - Armacell, a global leader in flexible foam for the equipment insulation market and a leading provider of engineered foams, announced its 9M 2019 results today.

During the first nine months of 2019, Armacell generated net sales of EUR 486.3 million, up by 5.9% compared to the same period last year on a like-for-like basis (9M 2018: EUR 459.2 million). Net sales growth was driven by volume growth in the Advanced Insulation business and by the fast-growing global PET business.

Adjusted EBITDA for the first nine months 2019 grew to EUR 98.1 million (9M 2018: EUR 77.8 million). The adoption of IFRS 16 accounted for EUR 8.9 million. The adjusted EBITDA margin reached 20.2%.

Commenting on the company's financial performance, Patrick Mathieu, President & CEO of the Armacell Group, said: "In Q3 2019, Armacell continued delivering strong profitable growth. Our organic growth performance is on track and we again saw a positive contribution from recent acquisitions and projects implemented in 2018. More recently, we commissioned a five-year expansion program for our global PET business and launched the industrial aerogel blanket line at our new South Korean facility."

Dr Max Padberg, CFO of the Armacell Group, added: "The strong EBITDA increase during the first nine months of the year was mainly driven by sales price increases, freight cost optimisation and efficiency gains. Our strong operating free cash flow in the first nine months of 2019 reduced our leverage ratio to 5x from approximately 6x at the beginning of this year."

Armacell is rated B (stable) by Standard & Poor's and B3 (stable) by Moody's.

-ends-

 

About Armacell
As the inventors of flexible foam for equipment insulation and a leading provider of engineered foams, Armacell develops innovative and safe thermal, acoustic and mechanical solutions that create sustainable value for its customers. Armacell's products significantly contribute to global energy efficiency making a difference around the world every day. With 3,100 employees and 24 production plants in 16 countries, the company operates two main businesses, Advanced Insulation and Engineered Foams, and generated net sales of EUR 610 million and adjusted EBITDA of EUR 106 million in 2018. Armacell focuses on insulation materials for technical equipment, high-performance foams for high-tech and lightweight applications and next generation aerogel blanket technology.

For more information, please visit:

Contacts

Corporate Investors
Tom Anen

Norman R. Rafael



12.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


910001  12.11.2019 

fncls.ssp?fn=show_t_gif&application_id=910001&application_name=news&site_id=research_pool
EN
12/11/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch